Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more
Blueprint Medicines Corp (BPMC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.159x
Based on the latest financial reports, Blueprint Medicines Corp (BPMC) has a cash flow conversion efficiency ratio of -0.159x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.48 Million) by net assets ($342.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Blueprint Medicines Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Blueprint Medicines Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Blueprint Medicines Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Blueprint Medicines Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Toppan Inc
PINK:TONPF
|
0.028x |
|
Doosan
KO:000150
|
0.010x |
|
BAWAG Group AG
PINK:BWAGF
|
0.135x |
|
UGI Corporation
NYSE:UGI
|
0.013x |
|
TFI International Inc
NYSE:TFII
|
0.096x |
|
Valmont Industries Inc
NYSE:VMI
|
0.068x |
|
Columbia Banking System Inc
NASDAQ:COLB
|
0.036x |
|
Viper Energy Ut
NASDAQ:VNOM
|
0.026x |
Annual Cash Flow Conversion Efficiency for Blueprint Medicines Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Blueprint Medicines Corp from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $298.67 Million | $-192.59 Million | -0.645x | +80.72% |
| 2023-12-31 | $130.61 Million | $-436.85 Million | -3.345x | -242.73% |
| 2022-12-31 | $514.68 Million | $-502.28 Million | -0.976x | -217.21% |
| 2021-12-31 | $970.74 Million | $-298.65 Million | -0.308x | -216.86% |
| 2020-12-31 | $1.47 Billion | $387.04 Million | 0.263x | +143.97% |
| 2019-12-31 | $464.36 Million | $-278.01 Million | -0.599x | -43.34% |
| 2018-12-31 | $419.01 Million | $-175.01 Million | -0.418x | -117.42% |
| 2017-12-31 | $623.97 Million | $-119.86 Million | -0.192x | -66.98% |
| 2016-12-31 | $213.08 Million | $-24.51 Million | -0.115x | +47.71% |
| 2015-12-31 | $143.98 Million | $-31.68 Million | -0.220x | +77.98% |
| 2014-12-31 | $35.43 Million | $-35.40 Million | -0.999x | -107.86% |
| 2013-12-31 | $-1.50 Million | $-19.02 Million | 12.717x | -- |